Raymond James lowered the firm’s price target on Abbott to $124 from $127 and keeps an Outperform rating on the shares. The underlying momentum is strong off of challenging comparisons even though Covid-testing comps distorted the reported results, the analyst tells investors in a research note. The testing comps will start to ease, which will help the growth optics, and Raymond James expects Abbott to continue to deliver a differentiated growth profile that should stand out in large cap healthcare.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- 3 Best Stocks to Buy Now, 4/18/2024, According to Top Analysts
- ABT Earnings: Abbott Beats Expectations with Q1 Earnings
- Abbott reports Q1 worldwide COVID-19 testing sales $204M vs. $730M last year
- Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges
- Abbott reports Q1 worldwide Medical Devices sales up 14.2% on reported basis